Dutch biotechnology company Mucosis B.V. today announced the appointment of Thomas Johnston as Chief Business Officer. In this role he will have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances.
Mr. Johnston joins Mucosis from Novavax Inc, a Nasdaq-listed clinical-stage biopharmaceutical company. As Vice President of Strategy he developed and executed a regional partnership strategy with deals in India, Mexico and South Korea. Prior to Novavax, Mr. Johnston served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with a number of world-class organizations such as Comcast, Microsoft, and Schlumberger. Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.
“Tom has more than 15 years of business development experience and an in-depth understanding of the vaccine and biotechnology space. Therefore we are very pleased to welcome him to our team.” said Govert Schouten, Chief Executive Officer of Mucosis. “Through this appointment, we extend our business development reach for the success of our Mimopath™-based vaccine candidates.”
Tom Johnston added: “I am excited to join the Mucosis management team. The company has made great progress to date and is now ready to move to broadening market awareness of its technology platform and vaccine pipeline.”
